A citation-based method for searching scientific literature

Sahar J Alothman, Weisheng Wang, David S Goerlitz, Md Islam, Xiaogang Zhong, Archana Kishore, Redha I Azhar, Bhaskar V Kallakury, Priscilla A Furth. Cancer Prev Res (Phila) 2017
Times Cited: 3







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.
Virginie Ory, William B Kietzman, Jacob Boeckelman, Bhaskar V Kallakury, Anton Wellstein, Priscilla A Furth, Anna T Riegel. Breast Cancer Res Treat 2018
10
66

Pioglitazone, a PPARγ agonist, suppresses CYP19 transcription: evidence for involvement of 15-hydroxyprostaglandin dehydrogenase and BRCA1.
Kotha Subbaramaiah, Louise R Howe, Xi Kathy Zhou, Peiying Yang, Clifford A Hudis, Levy Kopelovich, Andrew J Dannenberg. Cancer Prev Res (Phila) 2012
23
66


Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
Sabine Heublein, Doris Mayr, Alfons Meindl, Alexandra Kircher, Udo Jeschke, Nina Ditsch. J Exp Clin Cancer Res 2017
14
66

BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Rohini Roy, Jarin Chun, Simon N Powell. Nat Rev Cancer 2011
695
33


A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516.
Kazuya Arai, Takanori Eguchi, M Mamunur Rahman, Ruriko Sakamoto, Norio Masuda, Tetsuya Nakatsura, Stuart K Calderwood, Ken-Ichi Kozaki, Manabu Itoh. PLoS One 2016
37
33

Brown vs white adipocytes: the PPARgamma coregulator story.
Arjen Koppen, Eric Kalkhoven. FEBS Lett 2010
77
33

Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma.
Maddalena T Tilli, M Silvina Frech, Mary E Steed, Kathleen S Hruska, Michael D Johnson, Jodi A Flaws, Priscilla A Furth. Am J Pathol 2003
42
33

Distinct gene regulatory programs define the inhibitory effects of liver X receptors and PPARG on cancer cell proliferation.
Daniel Savic, Ryne C Ramaker, Brian S Roberts, Emma C Dean, Todd C Burwell, Sarah K Meadows, Sara J Cooper, Michael J Garabedian, Jason Gertz, Richard M Myers. Genome Med 2016
24
33

Stromal adipocyte PPARγ protects against breast tumorigenesis.
Graham Skelhorne-Gross, Alexis L Reid, Anthony J Apostoli, Michael A Di Lena, Rachel E Rubino, Nichole T Peterson, Mark Schneider, Sandip K SenGupta, Frank J Gonzalez, Christopher J B Nicol. Carcinogenesis 2012
20
33

Suppression of Rat Oral Carcinogenesis by Agonists of Peroxisome Proliferator Activated Receptor γ.
David L McCormick, Thomas L Horn, William D Johnson, Xinjian Peng, Ronald A Lubet, Vernon E Steele. PLoS One 2015
10
33

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.
Veronica Vella, Maria Luisa Nicolosi, Stefania Giuliano, Maria Bellomo, Antonino Belfiore, Roberta Malaguarnera. Front Endocrinol (Lausanne) 2017
46
33

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Yoshito Komatsu, Takayuki Yoshino, Kentaro Yamazaki, Satoshi Yuki, Nozomu Machida, Takahide Sasaki, Ichinosuke Hyodo, Yutaka Yachi, Hiroshi Onuma, Atsushi Ohtsu. Invest New Drugs 2014
16
33

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Francisco J Esteva, Stacy L Moulder, Ana M Gonzalez-Angulo, Joe Ensor, James L Murray, Marjorie C Green, Kimberly B Koenig, Mong-Hong Lee, Gabriel N Hortobagyi, Sai-Ching Yeung. Cancer Chemother Pharmacol 2013
26
33


Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.
R C Smallridge, J A Copland, M S Brose, J T Wadsworth, Y Houvras, M E Menefee, K C Bible, M H Shah, A W Gramza, J P Klopper,[...]. J Clin Endocrinol Metab 2013
67
33


The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
I Borbath, I Leclercq, P Moulin, C Sempoux, Y Horsmans. Eur J Cancer 2007
39
33

Safety issues and prospects for future generations of PPAR modulators.
Anne Rubenstrunk, Rémy Hanf, Dean W Hum, Jean-Charles Fruchart, Bart Staels. Biochim Biophys Acta 2007
222
33

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander,[...]. J Clin Oncol 2013
108
33

Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
Silvia Martina Ferrari, Gabriele Materazzi, Enke Baldini, Salvatore Ulisse, Paolo Miccoli, Alessandro Antonelli, Poupak Fallahi. Curr Med Chem 2016
10
33

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Joanne Kotsopoulos, Christian Singer, Steven A Narod. Breast Cancer Res Treat 2017
15
33

Prevention of ER-negative breast cancer.
Yuxin Li, Powel H Brown. Recent Results Cancer Res 2009
19
33

RANKL/RANK control Brca1 mutation- .
Verena Sigl, Kwadwo Owusu-Boaitey, Purna A Joshi, Anoop Kavirayani, Gerald Wirnsberger, Maria Novatchkova, Ivona Kozieradzki, Daniel Schramek, Nnamdi Edokobi, Jerome Hersl,[...]. Cell Res 2016
82
33

The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
Giuseppe Derosa, Amirhossein Sahebkar, Pamela Maffioli. J Cell Physiol 2018
77
33

Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.
Hilal Kocdor, Mehmet Ali Kocdor, Tulay Canda, Duygu Gurel, Ruksan Cehreli, Osman Yilmaz, Mehmet Alakavuklar, Gul Guner. Clin Transl Oncol 2009
11
33

Accurate classification of BRCA1 variants with saturation genome editing.
Gregory M Findlay, Riza M Daza, Beth Martin, Melissa D Zhang, Anh P Leith, Molly Gasperini, Joseph D Janizek, Xingfan Huang, Lea M Starita, Jay Shendure. Nature 2018
224
33

Cancer genetics, precision prevention and a call to action.
Clare Turnbull, Amit Sud, Richard S Houlston. Nat Genet 2018
50
33

Role of high-fat diet on the effect of pioglitazone and melatonin in a rat model of breast cancer.
Bianka Bojková, Peter Orendáš, Karol Kajo, Peter Kubatka, Desanka Výbohová, Soňa Bálentová, Peter Kružliak, Anthony Zulli, Vlasta Demečková, Martin Péč,[...]. Eur J Cancer Prev 2016
5
33

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention.
Jeffrey M Peters, Yatrik M Shah, Frank J Gonzalez. Nat Rev Cancer 2012
270
33

The role of BRCA1 in transcriptional regulation and cell cycle control.
P B Mullan, J E Quinn, D P Harkin. Oncogene 2006
191
33

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
Michael J Pishvaian, John L Marshall, Andrew J Wagner, Jimmy J Hwang, Shakun Malik, Ion Cotarla, John F Deeken, A Ruth He, Hirut Daniel, Abdel-Baset Halim,[...]. Cancer 2012
45
33

PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
W Ahmed, O Ziouzenkova, J Brown, P Devchand, S Francis, M Kadakia, T Kanda, G Orasanu, M Sharlach, F Zandbergen,[...]. J Intern Med 2007
92
33

Mouse models of breast cancer metastasis.
Anna Fantozzi, Gerhard Christofori. Breast Cancer Res 2006
184
33

Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1.
Krishna K Singh, Praphulla C Shukla, Bobby Yanagawa, Adrian Quan, Fina Lovren, Yi Pan, Cory S Wagg, Hwee Teoh, Gary D Lopaschuk, Subodh Verma. J Thorac Cardiovasc Surg 2013
18
33


Primary cancer cell culture: mammary-optimized vs conditional reprogramming.
Ahmad M Alamri, Keunsoo Kang, Svenja Groeneveld, Weisheng Wang, Xiaogang Zhong, Bhaskar Kallakury, Lothar Hennighausen, Xuefeng Liu, Priscilla A Furth. Endocr Relat Cancer 2016
9
33

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Pascal Pujol, Christine Lasset, Pascaline Berthet, Catherine Dugast, Suzette Delaloge, Jean-Pierre Fricker, Isabelle Tennevet, Nathalie Chabbert-Buffet, Pascale This, Karen Baudry,[...]. Fam Cancer 2012
20
33

PPARγ agonists target aromatase via both PGE2 and BRCA1.
Ofer Margalit, Dingzhi Wang, Raymond N Dubois. Cancer Prev Res (Phila) 2012
8
33

PPARγ signaling and emerging opportunities for improved therapeutics.
Shuibang Wang, Edward J Dougherty, Robert L Danner. Pharmacol Res 2016
64
33

Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers.
Lisa D Yee, Nita Williams, Ping Wen, Donn C Young, Joanne Lester, Maria V Johnson, William B Farrar, Michael J Walker, Stephen P Povoski, Saul Suster,[...]. Clin Cancer Res 2007
72
33

Drug development for cancer chemoprevention: focus on molecular targets.
Karen A Johnson, Powel H Brown. Semin Oncol 2010
45
33

Out-RANKing BRCA1 in Mutation Carriers.
Emma Nolan, Geoffrey J Lindeman, Jane E Visvader. Cancer Res 2017
21
33

Standards for Cell Line Authentication and Beyond.
Jamie L Almeida, Kenneth D Cole, Anne L Plant. PLoS Biol 2016
58
33


Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Sarah A Dabydeen, Keunsoo Kang, Edgar S Díaz-Cruz, Ahmad Alamri, Margaret L Axelrod, Kerrie B Bouker, Rawan Al-Kharboosh, Robert Clarke, Lothar Hennighausen, Priscilla A Furth. Carcinogenesis 2015
12
33

PPARγ and Its Role in Cardiovascular Diseases.
Mini Chandra, Sumitra Miriyala, Manikandan Panchatcharam. PPAR Res 2017
34
33

Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors.
Haruyasu Murakami, Akira Ono, Toshiaki Takahashi, Yusuke Onozawa, Takahiro Tsushima, Kentaro Yamazaki, Takahiro Jikoh, Narikazu Boku, Nobuyuki Yamamoto. Anticancer Res 2014
12
33

Modifiable Lifestyle Factors: Opportunities for (Hereditary) Breast Cancer Prevention - a Narrative Review.
Jacqueline Lammert, Sabine Grill, Marion Kiechle. Breast Care (Basel) 2018
10
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.